Clinical Trial Update: BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for AVZO-103 as a single agent and in combination therapy for locally advanced or metastatic urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• AVZO-103

Snippet

Sponsor: Avenzo Therapeutics, Inc. | Conditions: Solid Tumor Cancer, Locally Advanced | Phase 1, Phase 2 | Status: RECRUITING